CD274 and neoplasm: In addition, immunohistochemical evaluation of programmed death‐ligand 1 (PD‐L1) in tumor cells is currently approved as a potential biomarker for predicting the clinical efficacy of ICI, by such as anti‐ programmed death 1 (PD‐1) antibodies.19